RENGİN BAYDAR, AYŞE ESRA KARADAĞ, SEVDE NUR BİLTEKİN, ETİL GÜZELMERİÇ, FATİH DEMİRCİ
Acta Pharmaceutica Sciencia - 2024;62(1):183-192
Tanacetum parthenium L. (Feverfew) is daisy-like Asteraceae plant carrying sesquiterpene lactones; used for the treatment of migraine and anti-inflammatory effect. This study aims to evaluate T. parthenium extract and major metabolite parthenolide for in vitro COX-1/COX-2, LOX inhibitory activity. The extract analyzed by HPTLC. To evaluate COX-1/COX-2 inhibition assays, studied with commercial kits (20µg/mL concentration for extract, 5 µg/mL for parthenolide). The major component of extract characterized as parthenolide. IC50 values for COX-1/COX-2 inhibition of extract were 10.45 and 9.81µg/mL, for parthenolide; 4.86 and 1.90µg/mL. SI values of T. parthenium extract and parthenolide were 0.93 and 0.39. Extract showed selective COX-2 inhibitory activity. The inhibition value of extract on LOX was 80% and inhibition value of parthenolide was 41.13%. The results suggested that T. parthenium extract showed selective potential for COX-2 enzyme inhibition. To the best of our knowledge, the extract was tested with COX-1, COX-2, and LOX enzymes for the first time.
